文献速递肺外科

影像学纯实性临床IA3期肺癌肺段切除术的肿瘤控制效果

Segmentectomy for cancer control in radiologically pure-solid clinical stage IA3 lung cancer.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2023-01-01

本研究比较影像学纯实性临床IA3期非小细胞肺癌患者行肺段切除术与肺叶切除术后的肿瘤控制效果。2010至2019年间3家机构共412例患者纳入分析,倾向性评分调整后,两组累积复发率无显著差异(5年率21.9% vs 20.8%,P=0.88),多变量分析中肺段切除术并非独立预后因素(HR 1.045,95%CI 0.475-2.298,P=0.91)。结论认为两组肿瘤控制可能相当,需进一步研究明确肺段切除术的生存获益。

要点

  • 影像学纯实性临床IA3期NSCLC行肺段切除术与肺叶切除术的累积复发率无显著差异。
  • 多变量分析中肺段切除术(对比肺叶切除术)非累积复发率的独立预后因素(HR 1.045,95%CI 0.475-2.298,P=0.91)。
  • 倾向性评分匹配40对后两组累积复发率仍无显著差异(5年率20.7% vs 18.4%,P=0.81)。

核心结论

  • 影像学纯实性临床IA3期非小细胞肺癌患者中,肺段切除术与肺叶切除术的肿瘤控制可能相当。
  • 需进一步研究以明确肺段切除术在这些患者中的生存获益。

研究设计与样本

  • 回顾性多机构研究,纳入2010至2019年间3家机构接受肺叶切除术或肺段切除术的影像学纯实性临床IA3期NSCLC患者412例。
  • 采用倾向性评分调整年龄、性别、吸烟史、肿瘤大小、18F-氟脱氧葡萄糖正电子发射断层扫描最大标准化摄取值、淋巴结清扫、组织学类型及淋巴管、血管和胸膜侵犯等混杂变量。
  • 主要终点为累积复发率(CIR)。

主要发现

  • 412例患者中,肺段切除术组44例中7例(15.9%)术后复发,肺叶切除术组368例中71例(19.3%)术后复发。
  • 肺段切除术组5年CIR为21.9%,肺叶切除术组为20.8%(P=0.88)。
  • 肺段切除术组局部区域复发率为6.8%,肺叶切除术组为9.0%。
  • 多变量分析中,肺段切除术(对比肺叶切除术)非CIR的独立预后因素(HR 1.045,95%CI 0.475-2.298,P=0.91)。
  • 倾向性评分匹配40对后,肺段切除术组5年CIR为20.7%,肺叶切除术组为18.4%(P=0.81)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需进一步研究以明确肺段切除术在这些患者中的生存获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to compare cancer control after segmentectomy and lobectomy in patients with radiologically pure-solid clinical stage IA3 non-small-cell lung cancer (NSCLC). METHODS: Patients with radiologically pure-solid clinical stage IA3 NSCLC who underwent lobectomy or segmentectomy at 3 institutions between 2010 and 2019 were identified. We estimated propensity scores to adjust for confounding variables regarding tumour malignancy, including age, sex, smoking history, tumour size, maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography, lymph node dissection, histological type and lymphatic, vascular and pleural invasion. Cumulative incidence of recurrence (CIR) was evaluated as a primary end point. RESULTS: Among 412 patients, postoperative recurrence occurred in 7 of 44 patients (15.9%) undergoing segmentectomy, and 71 of 368 patients (19.3%) undergoing lobectomy. CIR was comparable between patients undergoing segmentectomy (5-year rate, 21.9%) and those undergoing lobectomy (5-year rate, 20.8%; P = 0.88). Locoregional recurrence did not differ between patients undergoing segmentectomy (6.8%) and those undergoing lobectomy (9.0%). In multivariable analysis, segmentectomy (versus lobectomy) was not identified as an independent prognostic factor for CIR (hazard ratio, 1.045; 95% confidence interval, 0.475-2.298; P = 0.91). In propensity score matching of 40 pairs, CIR was not significantly different between patients undergoing segmentectomy (5-year rate, 20.7%) and those undergoing lobectomy (5-year rate, 18.4%; P = 0.81). CONCLUSIONS: Cancer control may be comparable between segmentectomy and lobectomy in patients with radiologically pure-solid clinical stage IA3 NSCLC. Further studies are warranted to clarify the survival benefits of segmentectomy in these patients.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Kamigaichi A, Mimae T, Tsubokawa N, et al. Segmentectomy for cancer control in radiologically pure-solid clinical stage IA3 lung cancer. Interdiscip Cardiovasc Thorac Surg. 2023. PMID: 37589650. doi:10.1093/icvts/ivad138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。